Interim Business Results - Operating revenue reached RMB 23.32 billion, a 4% year-over-year increase[11] - Profit from operations amounted to RMB 2.91 billion, an 8% year-over-year increase[11] - Total profit reached RMB 2.57 billion, a 7% year-over-year increase[11] - EBITDA reached RMB 6.48 billion, a 10% year-over-year increase[11] - Net profit reached RMB 2.08 billion, a 22% year-over-year increase[11] - EPS reached RMB 0.41, a 24% year-over-year increase[11] Business Segments - Drilling segment operating profit increased by RMB 0.31 billion year-over-year[16] - Technology segment maintained relatively high profitability[15] Operational Efficiency - Cost profit margin increased from 10% in 1H2024 to 11.2% in 1H2025[28] - Operating profit margin increased from 11.1% in 1H2024 to 12.4% in 1H2025[28] Overseas Operations - Overseas sales revenue and profitability have continued to grow[41]

Financial Performance - The company's underlying profit decreased by 1% year-over-year to HK$5,118 million[13, 15] - Net profit attributable to shareholders decreased by 8.7% year-over-year to HK$4,019 million[13, 15, 16] - Underlying earnings per share (EPS) decreased by 4.9% year-over-year to HK$0.58[13, 15] - Revenue decreased by 6.6% year-over-year to HK$8,183 million, mainly due to a HK$668 million reduction in property sales[15] - Net cash increased by HK$3,876 million year-over-year, reaching HK$49,461 million[13, 19] Segment Performance - Property sales profit contribution increased by 28.4% to HK$1,030 million, driven by an enhancement in segment gross profit margin[17] - Property rental profit contribution decreased by 4.4% to HK$2,799 million due to the full-year effect of the discontinuation of waiver fee concession[17] - Hotel operations profit contribution decreased by 2.5% to HK$475 million, impacted by downward pressure on room rates in Hong Kong and Singapore[17] Land Bank and Property Sales - The company has an attributable land bank of 18.9 million square feet as of June 30, 2025[22] - Property sales recognized in the financial year increased by 21.6% to HK$10,813 million, with a gross profit margin of 9.4%[37] - Total attributable contracted sales of over HK$4 billion have not yet been recognized[39] Property Rental and Investment Properties - Overall occupancy rate slightly decreased to 89.6%[53] - Revaluation loss on investment properties (net of deferred taxation) was HK$1,084 million[16, 65] - Total attributable value of investment properties increased by 0.9% to HK$89,137 million[65]

Financial Performance Highlights - The Group's insurance revenue reached RMB 280250 million, a 71% increase[101] - Net profit attributable to equity holders of the company increased by 140% to RMB 26671 million[19,101] - The Group's total investment yield (annualized) was 50%, up 09 percentage points[22,101] - Group consolidated net assets increased by 63% to RMB 3906 billion[20,41] Business Segment Performance - PICC P&C's insurance revenue grew by 56% to RMB 249040 million, with a combined ratio of 948%[57,101] - PICC Life's insurance revenue increased significantly by 325% to RMB 14018 million[68,101] - PICC Health saw a 132% rise in insurance revenue, reaching RMB 15603 million[74,101] Strategic Focus and Initiatives - The group premiums income increased by 64% to RMB 4546 billion[26] - Total insurance investment assets grew by 72% to RMB 17607 billion[32] - Business synergy generated RMB 16 billion in premiums income, an 89% increase[37] - The company is focused on strengthening core functions, promoting "Six Reforms," high-quality development, and risk prevention in the second half of 2025[90,91,92,93]

August 2025 2025 FIRST HALF RESULTS REVIEW O U R B U S I N E S S 2025 First Half Results Review ~ Stock Code: 0270 F I N A N C I A L H I G H L I G H T S 1 The unaudited consolidated profit attributable to owners of the Company for 1H25 increased by 11.2% to HK$2,682 million and interim dividend per share increased by 11.2% to HK$26.66 cents. 2 The net finance costs from continuing operations was decreased by HK$201 million to HK$188 million and net loss arising from fair value adjustments for investment pro ...

BOARD AND MANAGEMENT INTERIM RESULTS PRESENTATION AUGUST 27, 2025 DISCLAIMER This presentation contains forward-looking statements that involve risks and uncertainties. These statements are generally indicated by the use of forward-looking terminology such as "believe", "expect", "anticipate", "estimate", "plan", "project", "target", "may", "will" or other similar words that express an indication of actions or results of actions that may or are expected to occur in the future. You should not place undue rel ...

Business Highlights - Akeso's commercial sales revenue in 2025H1 reached RMB 1.402 billion, a 49% year-on-year increase[16, 24] - The company has 13 Phase III/registrational trials of ivonescimab covering lung cancer and expanding to cold tumors[13] - The company has 10 phase III clinical studies of cadonilimab across lung cancer, gastric cancer, liver cancer and cervical cancer[13] - Penpulimab receives FDA approval in the United States[14] Pipeline Development - Three blockbuster new drug candidates entered clinical stage[19] - Six Phase III clinical trials reached the primary endpoint[20] - Ivonescimab's first global Phase III trial received positive results[84] - Manfidokimab (IL-4Rα) Reached Endpoints in the Registrational Phase III Trial for Atopic Dermatitis[116] Financial Performance - 1H 2025 Revenue reached RMB 1.412 billion, a 33.7% growth from 1H in 2024[16] - The company has cash and short-term financial assets of approximately RMB 7.14 billion[16] - Sales and Marketing expense as a percentage of sales decreased from 55% in 2024H1 to 48% in 2025 H1[136, 140]

AGENDA 01. HIGHLIGHTS 04.ESG 02. FINANCIAL REVIEW 03.BUSINESS REVIEW 05. LAND BANK 06. OUTLOOK 07.APPENDIX 三亚海棠湾悦府 西安万象城 Xi'an Mixc P A R T PART ONE Results Highlights Strengthening Momentum of the Second Growth Curve for Stable Performance and Returns Revenue +19.9% YoY Recurring Income +2.5% YoY RMB 94.9bn RMB 20.6bn Weighted Average Funding Cost 2.79% -32bps from FY24 Attributable Net Profit +16.2% YoY Recurring Core Net Profit RMB 11.9 +9.6% YoY bn RMB 6.0bn Net Gearing Ratio 39.2% Core Net Profit -6.6% ...

Financial Performance - The company's revenue reached RMB 131867 million, a 25% year-over-year increase[11] - Gross profit increased to RMB 21510 million, representing a 28% increase[11] - Net profit attributable to shareholders was RMB 2077 million, a decrease of 203%[11] - Operating cash flow significantly improved, reaching RMB 1531 million, a 2501% increase compared to the previous year[11] Business Segments - Pharmaceutical manufacturing business revenue was RMB 2481 billion, up 43% year-over-year, while segment gross profit margin decreased by 08 percentage points to 593%[19, 20] - Commercial business revenue increased by 23% to RMB 108330 million[62] - The medical device business achieved revenue of RMB 18 billion, an 8% year-over-year increase[70] Strategic Initiatives - The company completed the acquisitions of Nigale and Tasly to expand into the medical device sector and solidify its position in the TCM industry[22, 24] - The company is committed to innovative R&D, with 476 total projects under research and development, including 178 new drugs[36] - The company is strengthening international expansion, with overseas API revenue reaching RMB 360 million in the first half of the year[53, 58]

Financial Performance - Clean Energy revenue significantly increased by 222% YoY[9], reaching RMB 9626 million[9] - Basic Earnings Per Share Increased to RMB 0278 per share[12] - Net Asset Value (NAV) per Share increased to RMB 6540 per share[14] - Annualised ROE Increased by 1pp to 97% YoY[15] - Overall Cash Conversion Cycle (CCC) was 25 days[18], optimised by 11 days YoY[18] Segment Results and Orders - Clean energy reportable segment profit increased significantly by 295% YoY[31], reaching RMB 560 million[31] - Newly signed orders for clean energy totaled RMB 897 billion[40], with offshore clean energy accounting for RMB 324 billion[40] - Backlog orders of clean energy stood at RMB 2520 billion[43], up 10% YoY[43] - Newly signed orders for liquid food reached RMB 690 million[40], a 62% QoQ increase from Q1 to Q2 in 2Q25[40] Business Highlights and Outlook - China's LNG imports declined by 206% YoY[59] to 3011 million tons[59] - The global tank container fleet reached 882023 units[147], representing an increase of 396% compared with 2024[147] - CLPT completed a new round of private placement in July 2025[154], raising RMB 110 million[154] and adding 19079434 new shares[154]

2025 Interim Results Presentation August 2025 China Everbright Environment Group Limited Forward-looking Statement This presentation may contain forward-looking statements. Any such forward-looking statements are based on a number of assumptions about the operations of China Everbright Environment (Group) Limited ("Everbright Environment" or the "Company", together with its subsidiaries, collectively the "Group") and factors beyond the Company's control and are subject to significant risks and uncertainties ...